Novo Nordisk initiated legal action against Eli Lilly in the U.S. District Court for the District of New Jersey, contending that the pharmaceutical company’s advertising campaigns for obesity and diabetes medications contain misleading claims about comparative effectiveness. The lawsuit centers on Lilly’s use of older clinical trial data to demonstrate superiority of its drugs over Novo’s products.
Novo specifically objected to nationwide advertisements that compare the highest doses of Lilly’s Zepbound obesity injection and Mounjaro diabetes medication against lower doses of Novo’s Wegovy injection. The Danish company argued that these campaigns fail to include recent data on a high-dose formulation of Wegovy that entered the market in March, which demonstrates weight loss results more aligned with Lilly’s offerings. Novo’s legal counsel stated that the comparison creates an inaccurate perception of Lilly’s superiority and that the company had previously issued a cease-and-desist request in April that Lilly declined to honor.
In its legal filing, Novo requested that the court permanently prohibit the advertising campaigns and mandate corrective advertising from Lilly. The company also seeks financial damages and indicated intentions to pursue a preliminary injunction to halt the ads immediately. Novo characterized the advertising as particularly problematic because consumers typically depend on promotional materials to understand GLP-1 medications, unlike healthcare providers who access comprehensive scientific information.
Lilly defended its advertising approach, emphasizing that it relies on established head-to-head clinical trials comparing Zepbound and Wegovy. The company stated its claims are truthful and grounded in rigorous scientific evidence. A television commercial cited in the lawsuit has reportedly achieved over 700 million impressions since airing in late April, demonstrating significant reach.
The lawsuit represents an escalation in competitive tension between the two companies within the GLP-1 market, where Lilly has captured substantial market share in recent years. Novo is leveraging multiple strategies to reclaim position, including strategic pricing adjustments, new formulations, and its obesity pill offering.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI